RNA-based medicines are one of the most promising ways to fight human disease, as demonstrated by the recent successes of RNA vaccines and double-stranded RNA (dsRNA) therapies. But while health care ...

The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it infects cells. Currently, no approved treatments exist. To address this critical ...

RNA-based medicines are one of the most promising ways to fight human disease, as demonstrated by the recent successes of RNA ...

Researchers studying gene expression have access to vast amounts of data from cells or tissues. This is thanks to advances in ...

The "Human Immunodeficiency Virus (HIV): Epidemiology Forecast to 2033" report has been added to ResearchAndMarkets.com's offering. This report provides an overview of the risk factors, comorbidities, ...

ViiV Healthcare has secured European Commission approval for its long-acting HIV treatment, Vocabria + Rekambys, for adolescents aged 12 and olde ...

A series of orders from the Trump administration have the potential to disrupt the delivery of life-saving medications to HIV ...

Updated recommendations were issued by the IAS-USA regarding the use of ART for treatment and prevention of HIV in adult populations.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Vocabria (cabotegravir ...